GLP-1 & Weight Management
Comprehensive research on GLP-1 receptor agonists including semaglutide, tirzepatide, and emerging weight management therapeutics.
23 research reports
Semaglutide: The Complete Scientific Guide - Mechanism, Dosing, Clinical Outcomes & Long-Term Safety (2025)
The most comprehensive research report on semaglutide (Ozempic, Wegovy, Rybelsus) ever published. 50,000+ words covering mechanism of action, every clinical trial, dosing protocols, weight loss outcomes, cardiovascular benefits, side effect management, compounding, and long-term safety data. Updated for 2025.
Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 Agonist - Complete Research Report
In-depth research report on tirzepatide (Mounjaro, Zepbound). Dual incretin mechanism, SURMOUNT trial data, weight loss up to 22.5%, diabetes management, and comparison to semaglutide.
Retatrutide: The Triple Hormone Agonist (GLP-1/GIP/Glucagon) - Phase 2 Data, Mechanism & Clinical Outlook
Complete research report on retatrutide (LY3437943), the first triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 trial data showing up to 24.2% weight loss, mechanism of action, and development timeline.
Liraglutide (Victoza/Saxenda): The First Daily GLP-1 Agonist - Clinical Data, Uses & Legacy
Comprehensive guide to <a href=
Dulaglutide (Trulicity): Weekly GLP-1 for Diabetes - Complete Clinical Profile & Outcomes Data
Research report on dulaglutide (Trulicity), the once-weekly GLP-1 receptor agonist for type 2 diabetes. AWARD trials, REWIND cardiovascular data, dosing, and comparison to other GLP-1s.
Exenatide (Byetta/Bydureon): The Original GLP-1 Agonist - History, Science & Clinical Data
Research report on exenatide, the first GLP-1 receptor agonist derived from Gila monster venom. Covers Byetta (twice-daily) and Bydureon (weekly) formulations, clinical data, and historical significance.
Survodutide: Glucagon/GLP-1 Dual Agonist for Obesity & NASH - Pipeline Analysis
Research report on survodutide (BI 456906), Boehringer Ingelheim
Orforglipron: The Oral Non-Peptide GLP-1 Agonist - A Fundamental change in Obesity Treatment
Research report on orforglipron (Eli Lilly), the first oral non-peptide GLP-1 receptor agonist. Phase 2 data, mechanism, and how oral daily pills could replace weekly injections.
CagriSema: Amylin + Semaglutide Combination - The Next Frontier in Weight Loss Pharmacotherapy
Research report on CagriSema (cagrilintide + semaglutide), Novo Nordisk
GLP-1 Receptor Agonists: Complete Class Overview - Every Drug, Every Trial, Every Comparison
The definitive comparison guide to all GLP-1 receptor agonists: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, and emerging agents. Head-to-head data, mechanism differences, and clinical recommendations.
How GLP-1 Drugs Cause Weight Loss: Complete Neurobiological & Metabolic Mechanisms
Detailed look into the mechanisms by which GLP-1 receptor agonists cause weight loss: appetite suppression, gastric emptying, brain signaling, metabolic rate effects, and emerging research on food reward pathways.
GLP-1 Agonists & Cardiovascular Health: MACE Reduction, Heart Failure, and Atherosclerosis
Comprehensive analysis of cardiovascular benefits of GLP-1 receptor agonists. Covers SELECT, LEADER, SUSTAIN-6, and REWIND trials showing reduced heart attacks, strokes, and cardiovascular death.
GLP-1 Side Effects: Complete Guide to Nausea, GI Issues, and Rare Complications
Everything about GLP-1 receptor agonist side effects: nausea management, GI tolerability, pancreatitis risk, thyroid concerns, gallbladder issues, and strategies to minimize adverse effects.
GLP-1 Compounding: Complete Guide to Compounded Semaglutide, Tirzepatide & Peptide Pharmacies
Everything about compounded GLP-1 medications: legal framework, quality considerations, pricing comparison, salt forms (sodium vs acetate), and how to evaluate compounding pharmacies.
Weight Regain After Stopping GLP-1 Drugs: Science, Data & Mitigation Strategies
What happens when you stop GLP-1 medications? Clinical data on weight regain, metabolic adaptation, strategies to maintain weight loss, and the debate around lifelong therapy.
Muscle Loss on GLP-1 Therapy: Quantifying Lean Mass Loss & Evidence-Based Prevention
How much muscle do you lose on GLP-1 drugs? Research data on lean mass changes, the role of protein intake, resistance training protocols, and combination strategies to preserve muscle.
GLP-1 Drugs & Addiction: Emerging Research on Alcohol, Nicotine & Substance Use Reduction
Emerging research on GLP-1 receptor agonists reducing alcohol consumption, nicotine cravings, and addictive behaviors. Mechanism of action in reward pathways, clinical evidence, and ongoing trials.
GLP-1 Agonists for Fatty Liver Disease (NAFLD/NASH/MASH): Clinical Evidence & Treatment Potential
How GLP-1 drugs treat non-alcoholic fatty liver disease. Clinical evidence for semaglutide, tirzepatide, and retatrutide in reducing liver fat, inflammation, and fibrosis.
GLP-1 Agonists & Kidney Disease: Renal Protection, CKD Outcomes & FLOW Trial Results
Evidence for GLP-1 receptor agonists in kidney disease protection. FLOW trial results for semaglutide, renal mechanisms, albuminuria reduction, and implications for chronic kidney disease treatment.
GLP-1 Drugs for Obstructive Sleep Apnea: Tirzepatide SURMOUNT-OSA Results & Clinical Implications
How GLP-1 agonists improve obstructive sleep apnea. SURMOUNT-OSA trial results, AHI reduction data, mechanism of improvement, and implications for CPAP alternatives.
Obesity Pharmacotherapy: Complete Guide to All FDA-Approved & Pipeline Weight Loss Drugs (2024-2025)
Comprehensive guide to all FDA-approved and pipeline obesity drugs. GLP-1s, dual/triple agonists, oral agents, myostatin inhibitors, and the future of weight management pharmacotherapy.
GLP-1 Drug Shortage Guide: Alternatives to Ozempic, Compounding Options & Switching Protocols
Navigating the GLP-1 drug shortage. Alternative GLP-1 medications, compounded semaglutide options, switching between drugs, dose equivalency, and maintaining treatment continuity.
GLP-1 Insurance Coverage: How to Get Ozempic & Mounjaro Covered, Prior Auth & Appeals Guide
Navigate insurance coverage for GLP-1 medications. Prior authorization strategies, appeal letter templates, manufacturer savings programs, cost-saving alternatives, and state-by-state coverage variations.